Pharmaceutical Technology

APRIL 7, 2023

The US Food and Drug Administration (FDA) has rescinded its approval for Swiss drug maker Covis Pharma’s (Covis) Makena drug and its generic versions , the only approved treatments aimed at reducing the risk of premature birth. Covis Pharma added the drug to its portfolio through the acquisition of AMAG Pharmaceuticals in November 2020.

Food and Drug Administration 97

Food and Drug Administration FDA Pharma Food 97

Pharmaceutical Technology

APRIL 7, 2023

The US Food and Drug Administration (FDA) has rescinded its approval for Swiss drug maker Covis Pharma’s (Covis) Makena drug and its generic versions , the only approved treatments aimed at reducing the risk of premature birth. Covis Pharma added the drug to its portfolio through the acquisition of AMAG Pharmaceuticals in November 2020.

Food and Drug Administration 95

Food and Drug Administration FDA Pharma Food 95

World of DTC Marketing

MAY 2, 2021

On a percentage basis, the figure for 2020 was Independence’s highest profit margin since 2011, records show. How does pharma respond? IBC, the Philadelphia region’s largest health insurer , on Tuesday reported 2020 net income of $622 million — almost double its $321 million income in 2019, before COVID-19 struck.

Healthcare 277

Healthcare Healthcare Insurance Government 277

World of DTC Marketing

AUGUST 27, 2021

The FDA approved 309 new drugs between 2011 and 2018, 38 per year on average. More than 40 million patients are needed to meet the demand of currently enrolling trials. According to antidote.com. More than 18,000 clinical trials are actively recruiting patients in the U.S. In 2018, the FDA approved 59 new drugs – an all-time high.

Recruitment 187

Recruitment Patients FDA Medical 187

World of DTC Marketing

AUGUST 1, 2022

Now, after the majority of voters want reduced costs for their prescription drugs, the bill seems ready to pass despite record pharma lobbying. According to a 2021 analysis , the number of hospice agencies owned by private equity firms soared from 106 of 3,162 hospices in 2011 to 409 of the 5,615 hospices operating in 2019.

Healthcare 234

Healthcare Healthcare Insurance Prescription 234

pharmaphorum

JANUARY 25, 2023

BMS’ lawsuit claims that Imjudo (tremelimumab) infringes two patents covering its own CTLA4 drug Yervoy (ipilimumab), which has been on the market since 2011 and is a key component of combination therapies for cancer with BMS’ PD-1 inhibitor Opdivo (nivolumab).

FDA 52

FDA Marketing Sales Pharma 52

Pharmaceutical Technology

NOVEMBER 3, 2022

A Quantitative View on Award Criteria in Tenders in the EU5 from 2011 to 2020 , Genane C, Trenti S In-Person and Virtual Poster Session 3 Date: Tuesday 8 November 2022 Poster Session Time: 10:00–13:15 HPR150: P&R Policies and Macro-Trends Pertinent to CGTs: Where Are the Main Barriers and Who Leads the Efforts to a Greater Access?

Pharma 52

Pharma Leads Medical Pharmaceutical 52

PM360

JUNE 29, 2022

The line from the 2011 Pixar “Cars” sequel (trust me, as a parent of two, I have seen it countless times) points to the practical implication for voice technology. How Pharma Marketers Can Adapt. Voice brings extraordinary potential for pharma marketers. “Everything is voice activated these days.”

Marketing 96

Marketing Healthcare Provider Prescription Patients 96

pharmaphorum

AUGUST 8, 2022

The GBT deal comes at a time when the market for SCD therapies is undergoing significant change, with multiple new drugs reaching the market after years of stagnation and progress also being made with genetic therapies from the likes of bluebird bio, Vertex Pharma/CRISPR Therapeutics and Precision Bio/Novartis.

Marketing 108

Marketing Sales Pharma FDA 108

pharmaphorum

DECEMBER 29, 2022

The case revolves around allegations that Novartis made an agreement in 2011 with Par Pharmaceutical when Exforge (valsartan/amlodipine) was nearing the end of its patent life that was designed to keep Par’s generic version of the drug off the market until 30 September, 2014.

Retail 52

Retail Marketing Doctors Government 52

European Pharmaceutical Review

FEBRUARY 1, 2024

Dr Michael Davidson is CEO of biotech company NewAmsterdam Pharma. We are hopeful that NewAmsterdam Pharma is part of that solution with obicetrapib.” NewAmsterdam Pharma is moving forward into our Phase III trials in the high LDL populations and ultimately, we want to show the benefit of obicetrapib on reducing cardiovascular events.

Pharma 76

Pharma Patients Pharmaceutical Leads 76

European Pharmaceutical Review

APRIL 8, 2024

Yet from 2011, these arrangements were the subject of “patent-non- exclusive rights, technology- exclusive rights and technology-supply”. Since 2010, some of the contracts for clinical development can be identified as being outsourced by existing mega pharma companies, the authors stated.

Manufacturing 52

Manufacturing Networking Pharmaceutical Marketing 52

pharmaphorum

JULY 6, 2022

A European Federation of Pharmaceutical Industries and Associations (EFPIA) report published earlier this year, for example, compared the timelines of six regulatory agencies between 2011 and 2020. She has worked on projects for pharma, charities, and agencies, and has written extensively for patients, HCPs and the public.

Safety 98

Safety FDA Medicine Patients 98

Pharmaceutical Technology

APRIL 27, 2023

The UK’s National Institute for Health and Care Excellence (NICE) has recommended two new personalised immunotherapy therapies from Kite Pharma to treat aggressive forms of blood cancer for the Cancer Drugs Fund (CDF). Established in 2011, the CDF is a source of funding to increase patient access to cancer drugs in the UK.

Patients 59

Patients Medicine Pharma Leads 59

pharmaphorum

NOVEMBER 6, 2022

Naturally, the pharma industry has seen an explosion of mAbs in the pipeline, which has led to the evolution of new methods for improving and refining the antibody pipeline. Four leading pharma companies – AstraZeneca, Merck, Pfizer, and Teva – along with Amazon Web Services, Inc. Disclosed Funding. Vancouver, Canada. ImmunitoAI.

Biopharma 115

Biopharma Pharma Training Leads 115

pharmaphorum

SEPTEMBER 30, 2022

Although the sticker shock that was at first associated with Yervoy (ipilimumab) in 2011 – in the early days of immuno-oncology monoclonal antibodies – has fallen by the wayside, especially in light of CAR-Ts and other “one and done” cell and gene therapies, the field of non-orphan oncology remains a target for cost savings by payers.

Consulting 92

Consulting Marketing Pharma Manufacturing 92

PM360

NOVEMBER 14, 2023

Through our Pharma Manufacturer Solutions offering, GoodRx has worked with 19 of the top 20 pharmaceutical manufacturers 1 to deliver savings options directly to relevant patients.

Retail 52

Retail Pharmaceutical manufacturing Sales Insurance 52

PM360

SEPTEMBER 21, 2023

Our solutions enable pharma manufacturers to engage with providers and patients so they can start and stay on the right medication and improve their health outcomes. Since GoodRx’s founding in 2011, we’ve seen firsthand that specialty brand drugs continue to have additional, more complex access and affordability barriers.

Prescription 52

Prescription Medical Patients Distribution 52

Pharmaceutical Technology

SEPTEMBER 13, 2022

With success in the metastatic setting, pharma companies, researchers and physicians have invested heavily in exploring the use of immune checkpoint inhibitors (ICIs) for the treatment of locally advanced disease, hoping to increase response rates and prevent disease progression.

Patients 69

Patients Physicians Safety Pharma 69

European Pharmaceutical Review

SEPTEMBER 14, 2023

For both small biotechs and large pharma, economic uncertainty is rising, intensifying decision-making risks associated with early drug discovery efforts, clinical trials, quality and manufacturing process execution, and navigating the approval process. 2011; 36(11):740-57. Mckinsey & Company. cited 2023September. Ventola CL.

Manufacturing 83

Manufacturing Engineering Management Pharmaceutical 83

Clarivate

MAY 24, 2022

Multinational pharmas seek entry for their products. Multinational pharmas have taken notice of the recent policy focus of Mainland China’s healthcare authorities on rare diseases. China’s rapidly evolving and increasingly dynamic rare disease market provides pharmas an opportunity for strong growth. 2011; 6:81-82. [3]

Patients 52

Patients Food and Drug Administration Marketing Pharma 52

Pharma Marketing Network

JUNE 10, 2020

RJ Lewis (EHS): Hello, this is RJ Lewis from Pharma Marketing Network. And he’s also a Pharma Marketing Network Editorial Advisory Board member. At the moment, it started off with, you know, five 8 10 million in 2011. Do you think that that’s happening within pharma now? I’ll be your host today.

Pharma 52

Pharma Marketing Doctors Recruitment 52

pharmaphorum

SEPTEMBER 16, 2022

Whilst many are rightly calling for a diversification and equitisation of clinical trial participation, it doesn’t yet change the fact that the pharma industry uses clinical research organisation (CRO)-provided information, which itself can only draw from the patient-provided data available – patient data which isn’t always particularly diverse.

Leads 132

Leads Patients Medicine FDA 132

European Pharmaceutical Review

JULY 21, 2023

A recent report from the US Food and Drug Administration (FDA) shows that while the number of new drug shortages has fallen significantly from a high of 250 in 2011 to 49 in 2022, there was an increase in new drug shortages year-on-year. Recommendations were also published earlier this year for all stakeholders in the pharma supply chain.

Pharmaceutical 95

Pharmaceutical Food and Drug Administration Transportation Manufacturing 95

Pharma Marketing Network

JUNE 10, 2020

RJ Lewis (EHS): Hello, this is RJ Lewis from Pharma Marketing Network. And he’s also a Pharma Marketing Network Editorial Advisory Board member. At the moment, it started off with, you know, five 8 10 million in 2011. Do you think that that’s happening within pharma now? I’ll be your host today.

Pharma 40

Pharma Marketing Doctors Recruitment 40

PM360

JUNE 11, 2022

Observationally, this is truer for the small and mid-size pharma and biotech companies than for larger pharma companies. In 2011, a trial by the British government failed to meet its goals, because it didn’t incorporate patient or caregiver input early, appropriately, or enough,” she says. “It What Even Is Patient Centricity?

Patients 98

Patients Medical Education Government 98

pharmaphorum

OCTOBER 12, 2022

By 2025, pharma’s investment in AI is expected to reach $3 billion. Understanding the need for AI to leverage data in a more systematic way in the development of genomic medicines, Whitelab Genomics’ software platform supports pharma from discovery through to designing the payload’s genetic construction and the vector’s composition.

Medicine 100

Medicine Patients Healthcare Healthcare 100

pharmaphorum

OCTOBER 31, 2022

He became CEO in 2011, as the company moved from purely consulting to developing forecast models, and has continued to evolve the business, using innovative technology to drive efficiencies for clients’ processes. About the author.

Pharmaceutical 52

Pharmaceutical Marketing Consulting Leads 52

PM360

DECEMBER 20, 2023

Additionally, it will delve into the current trends and challenges that pharma companies need to consider when devising successful market access strategies for this unique market. Trends and Characteristics of New Drug Approvals in China, 2011-2021.” References: 1. Su L, Liu S, Li G, Xie C, Yang H, Liu Y, Yin C, Chen X. Tomaszek, A.

Marketing 105

Marketing Insurance Medical Manufacturing 105

Evolve Your Success

MARCH 28, 2023

That was December of 2011. I don’t know much about pharma. I could probably find somebody that’s in pharma and message them on somebody’s behalf and introduce them. How long ago was this? January 2012 is when I started with that. It was a long time ago. So much has happened since then. It’s important.

Medical 52

Medical Sales Medical sales Training 52

Cadensee

JULY 26, 2021

I practiced law in one of Tel Aviv's biggest law firm, for about seven years, representing startup companies as well as some bigger pharma companies. So, all they knew are the protocols that are dominant in the pharma industry. Her previous venture PolyTouch Medical was acquired back in 2011.

Retail 52

Retail Marketing Doctors Food 52

Cadensee

JULY 14, 2021

So not only M&As, the tech, the retail, the pharma that are buying. Kind of funny, but in 2011 when you guys were children, we decided to do a course in Hilton Hotel here in Tel Aviv. So, digital health companies that became public either through an IPO or a SPAC.

Marketing 52

Marketing Doctors Medical Management 52